Compare Receptos vs Reprogenesis
Customers evaluate the quality of Receptos's products using the following success metrics.
Overview
Receptos is based in United States
Receptos (NASDAQ: RCPT) is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics in immune disease. The company's lead asset, RPC1063, is being developed as an oral therapy for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD). The goal of the company's development strategy for RPC1063 is to demonstrate clinically meaningful differentiation versus other available treatments, including a favorable safety profile.
Reprogenesis is 24 yrs old and is based in United States.
Reprogenesis is a therapeutic drug development company, focusing on regulatory pathways that control repair and regeneration using proteins or small molecules to modulate these pathways.
Demo Video
Leadership
Hugh Rosen (Founder)
Daniel R Omstead (Chief Executive Officer)
Investors
Celgene, Venrock
UBS, Narragansett Asset Management
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Receptos has not claimed their profile.
Work for Receptos? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Receptos?
Claim your profile now.
Information not available because Reprogenesis has not claimed their profile.
Work for Reprogenesis? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Reprogenesis?
Claim your profile now.